Lexaria Bioscience Corp. Common Stock
Veridion Score
Composite trend over time
Why is LEXX moving today?
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for LEXX.
LEXX insider activity
Lexaria Bioscience Corp. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for LEXX.
LEXX contract awards, year to date.
Public federal awards linked to this ticker.
LEXX lobbying filings, year to date.
Registered lobbying filings matched to Lexaria Bioscience Corp. Common Stock.